Patient derived renal cell carcinoma xenografts exhibit distinct sensitivity patterns in response to antiangiogenic therapy and constitute a suitable tool for biomarker development

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Systemic treatment is necessary for one third of patients with renal cell carcinoma. No valid biomarker is currently available to tailor personalized therapy. In this study we established a representative panel of patient derived xenograft (PDX) mouse models from patients with renal cell carcinomas and determined serum levels of high mobility group B1 (HMGB1) protein under treatment with sunitinib, pazopanib, sorafenib, axitinib, temsirolimus and bevacizumab. Serum HMGB1 levels were significantly higher in a subset of the PDX collection, which exhibited slower tumor growth during subsequent passages than tumors with low HMGB1 serum levels. Pre-treatment PDX serum HMGB1 levels also correlated with response to systemic treatment: PDX models with high HMGB1 levels predicted response to bevacizumab. Taken together, we provide for the first time evidence that the damage associated molecular pattern biomarker HMGB1 can predict response to systemic treatment with bevacizumab. Our data support the future evaluation of HMGB1 as a predictive biomarker for bevacizumab sensitivity in patients with renal cell carcinoma.

Original languageEnglish (US)
Pages (from-to)30946-30961
Number of pages16
JournalOncotarget
Volume9
Issue number57
DOIs
StatePublished - Jul 24 2018

    Fingerprint

Keywords

  • Bevacizumab
  • Damage associated molecular pattern
  • HMGB1
  • Renal cell carcinoma
  • VEGF

ASJC Scopus subject areas

  • Oncology

Cite this

Schueler, J., Klingner, K., Bug, D., Zoeller, C., Maier, A., Dong, M., Willecke, K., Peille, A. L., Steiner, E., Landesfeind, M., Copland, J. A. III., Siegers, G. M., Haferkamp, A., Boehm, K., Tsaur, I., & Schneider, M. (2018). Patient derived renal cell carcinoma xenografts exhibit distinct sensitivity patterns in response to antiangiogenic therapy and constitute a suitable tool for biomarker development. Oncotarget, 9(57), 30946-30961. https://doi.org/10.18632/oncotarget.25697